Blood Biomarkers of Alzheimer Disease and Rates of Global and Domain-Specific Cognitive Decline

What is the association of different blood-based biomarkers of Alzheimer disease (AD) with global and domain-specific cognitive decline in the general population? In this cohort study of 2008 older adult participants in the Swedish National Study on Aging and Care–Kungsholmen, AD-related biomarkers, especially phosphorylated tau 217, phosphorylated tau 181, neurofilament light chain, and glial fibrillary acidic protein, were associated with faster rates of cognitive decline over up to 15 years of follow-up. Associations differed depending on the biomarker measured and participant sex and APOE genotype. Easily accessible blood-based biomarkers of AD may be linked to subsequent faster cognitive decline in the general older population, with patterns suggesting some heterogeneity across biomarkers and that individual characteristics may influence clinical interpretation.

Corresponding Author: Erika J. Laukka, PhD, Aging Research Center, Tomtebodavägen 18A, 171 77 Stockholm, Sweden (Erika.Jonsson.Laukka@ki.se).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.